Jason Sims, MD
Interventional Cardiology · Rochester, MNNPI 1043699192
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Abbott at 51.2% of the total. Reporting peaked in 2024 at $1,355 and has fallen 83.2% since, to $227 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.
Across 31 payments — averaging $80.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Edwards Lifesciences$925
- Abiomed$181
- Kestra Medical Technology Services, Inc.$26
- Asahi Intecc USA, Inc.$23
- Medtronic$22
- plus $40 from 2 others
What the payments were for
- Travel & lodging$1,21249%
- Food & beverage$1,28151%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $1,277 |
| Edwards Lifesciences | 14 | $925 |
| Abiomed | 2 | $181 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Asahi Intecc USA, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Amgen | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,494 in reported general payments places this provider in the 30th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $135,667 |
| XareltoRivaroxaban | 27 | $41,862 |
| Repatha SyringeEvolocumab | 13 | $7,332 |
| Metoprolol Succinate | 237 | $3,705 |
| Atorvastatin Calcium | 176 | $2,084 |
| Ezetimibe | 79 | $1,683 |
| Rosuvastatin Calcium | 145 | $1,642 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 66 | $1,169 |
| Torsemide | 21 | $755 |
| Amlodipine Besylate | 128 | $751 |
| ClopidogrelClopidogrel Bisulfate | 86 | $707 |
| Pantoprazole Sodium | 25 | $628 |
| Lisinopril | 73 | $564 |
| Dilt-XrDiltiazem Hcl | 12 | $561 |
| Potassium Chloride | 29 | $549 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Rochester
- Kelley ChenRochester$14K
- Colleen LaneRochester$14K
- Smitha Narayana GowdaRochester$9K
- Trevor SimardRochester$9K
- Michael SabbahRochester$8K
- Aravdeep JhandRochester$7K
- Joshua RezkallaRochester$5K
- Mohammed OsmanRochester$4K
- Mohammad SarrafRochester$3K
- Conor LaneRochester$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.